<DOC>
	<DOC>NCT00600834</DOC>
	<brief_summary>The objective of this long term study is to prospectively compare the incidence of NSF in two cohorts (Cohort 1- patients with moderate chronic kidney disease eGFR 30-59 and Cohort 2- patients with severe chronic kidney disease or kidney failure eGFR &lt;30).</brief_summary>
	<brief_title>Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>COHORT 1 Is going to receive or has received PROHANCE injection during an MRI examination; Has CKD with eGFR stably comprised between 30 and 59 mL/min/1.73m2, as calculated from a SCr value obtained from the local laboratory within 24 hours prior to the PROHANCE injection. Provides written informed consent and is willing to comply with protocol requirements. OR COHORT 2 Is going to receive or has received PROHANCE injection during an MRI examination; Has CKD with eGFR below 30 mL/min/1.73m2, as calculated from a SCr value obtained from the local laboratory within 24 hours prior to the PROHANCE injection. Provides written informed consent and is willing to comply with protocol requirements. COHORT 1 Has received a GBCA within the past 12 months prior to inclusion in this study; Has unstable kidney function; Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data and achieving study objectives; Has ever been suspected of, or diagnosed with, NSF prior to the studyspecific MRI; Is unable or unwilling to return for necessary office visits, to be examined by dermatologists or to undergo deep skin biopsy should development of NSF be suspected. OR COHORT 2 Has received a GBCA within the past 12 months prior to inclusion in this study; Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data and achieving study objectives; Has ever been suspected of, or diagnosed with, NSF prior to the studyspecific MRI; Is unable or unwilling to return for necessary office visits, to be examined by dermatologists or to undergo deep skin biopsy should development of NSF be suspected.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>